Subjects currently using hormone replacement therapy,
Other Axis I disorders, except Generalized Anxiety Disorder or Panic Disorder, according to the Mini International Neuropsychiatric Interview (MINI)
"uncontrolled" narrow angle glaucoma
known hypersensitivity to duloxetine or any of the inactive ingredients
treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of randomization or potential need to use an MAOI during the study or within 5 days of discontinuation of study drug.
Presence of psychotic symptoms,
History of mania or hypomania,
HAM-D suicide item score \> 3,
End stage renal disease or severe renal impairment
Abnormal uterine bleeding (heavy or prolonged uterine bleeding, menstrual periods occurring more frequently than every 3 weeks, bleeding after sexual intercourse, spotting between periods) that has not been evaluated by a gynecologist.
Subjects with serious or unstable medical illness, including alcohol or substance abuse, cardiovascular, hepatic, respiratory, endocrine, neuralgic, or hematologic disease, history of seizure disorder
Subjects taking medications that may interact with duloxetine
